NBIXNeurocrine Biosciences, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for ~5% a year FCF growth. The price demands less than its three-year revenue growth of 26% a year, expectations look modest.
Cheap vs its own history: P/E 20.9 vs a 41.3 median over 25 quarters (−49% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NBIX's price assumes
Neurocrine Biosciences, Inc. trades at 20.9× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 1.06× the median: the market pays up for this one
- Price / sales
- 5.77
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 5.2%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +5.0%
Growth the price implies · The price pays for +5.0% free cash flow growth a year for a decade; the business has delivered +46% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 5.07
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 24.3
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 5.25
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $866M
- Market capitalisation
- $16.5B
- 3-year revenue growth
- +26%
- 3-year free cash flow growth
- +46%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $207.57 |
| Its own P/E history, median | $281.95 |
| Its own P/E history, upper quartile | $410.29 |
| 52-week range | $123.10 – $182.85 |
| Today | $142.40 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #6 of 41 by RyuScore